Dan P. Zandberg - Concepedia

Author

Dan P. Zandberg

Also Known As

D. P. Zandberg, D. Zandberg, D.P. Zandberg, Dan P. Zandberg, Dan P Zandberg, Dan P. Zandberg, Dan Paul Zandberg, Dan Zandberg, Daniel Zandberg, Dan P. Zandberg

230

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

UPMC Hillman Cancer Center University of Maryland, Baltimore University of Pittsburgh Medical Center University of Pittsburgh Princess Margaret Cancer Centre

About

Dan P. Zandberg is an author at UPMC Hillman Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	3.2K
2	Health Sciences	6	6	846
3	Epidemiology	2	2	44
4	Public Health	1	1	13
5	Cell Biology	1	1	121

Dan P. Zandberg

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, The Lancet MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology	2018	1.6K
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) Ezra E.W. Cohen, R. Bryan Bell, Carlo Bifulco, Journal for ImmunoTherapy of Cancer Neoadjuvant TherapySquamous Cell CarcinomaImmunologyPathologyRecurrent Hnscc	2019	712
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC Lillian L. Siu, Caroline Even, Éva Remenár, JAMA Oncology	2018	306
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno, European Journal of Cancer	2018	262
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial Charu Aggarwal, Amy Prawira, Scott Antonia, Journal for ImmunoTherapy of Cancer	2022	131
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck Dan P. Zandberg, Ashley V. Menk, Maria Velez, Journal for ImmunoTherapy of Cancer Squamous Cell CarcinomaPd-1 BlockadeImmunologyPathologyMetronomic Chemotherapy	2021	121
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort Neil H. Segal, Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian, European Journal of Cancer MedicineCancer ManagementPathologyMolecular OncologyHead And Neck Cancer	2019	85
Transition to a virtual multidisciplinary tumor board during the <scp>COVID</scp>‐19 pandemic: University of Pittsburgh experience Harish Dharmarajan, Jennifer L. Anderson, Seungwon Kim, Head & Neck	2020	82
Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Neil H. Segal, Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian, Journal of Clinical Oncology Squamous Cell CarcinomaImmunologyImmunoeditingPathologyImmunotherapeutics	2015	79
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) Dan P. Zandberg, Sandra Rollins, Olga Goloubeva, Cancer Immunology Immunotherapy VaccinationEscalation TrialTumor ImmunologySquamous Cell CarcinomaMedicine	2014	74

Page 1